Literature DB >> 11680569

Total and active thymoglobulin levels: effects of dose and sensitization on serum concentrations.

J F Regan1, C Lyonnais, K Campbell, L V Smith, R Buelow.   

Abstract

A group of 79 renal transplant patients undergoing acute rejection episodes were treated with Thymoglobulin (rabbit anti-thymocyte globulin), 1.5 mg/kg/day for 6-14 days as part of a double-blinded trial comparing the efficacy of Thymoglobulin and Atgam (horse anti-thymocyte globulin). Serial serum samples from the patients were tested to determine the level of Thymoglobulin (i.e. rabbit IgG levels = total Thymoglobulin) and anti-Thymoglobulin using ELISAs. Antibodies binding to human lymphocytes (active Thymoglobulin), were determined by flow cytometry; no correlation was seen between treatment efficacy and either active or total Thymoglobulin concentrations; the overall treatment success rate was 86%. Pharmacokinetics of total and active Thymoglobulin were distinctly different; active Thymoglobulin disappeared much more rapidly: only 12% of patients had detectable active Thymoglobulin by day 90 compared to 81% of patients with detectable total Thymoglobulin; percent active Thymoglobulin decreased from a peak of 0.56-0.7% during treatment, to 0.07-0.35% by day 21, and less than 0.14% by day 30. Thymoglobulin and active Thymoglobulin concentrations were modeled by multiple regression. Using dose number and sensitization as independent variables, 47-76% of the variability seen in interpatient Thymoglobulin levels could be explained, while for active Thymoglobulin levels, the measured variables accounted for 13-48% of the observed interpatient variation. We conclude that: (1) for a group of patients receiving primary Thymoglobulin treatment (averaging nine full and one partial dose per patient), neither Thymoglobulin nor active Thymoglobulin levels are predictive of treatment outcome; (2) active Thymoglobulin disappears more rapidly from the circulation than total Thymoglobulin; and (3) patients that develop anti-rabbit IgG antibodies clear Thymoglobulin and active Thymoglobulin more rapidly than unsensitized patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11680569     DOI: 10.1016/s0966-3274(01)00048-x

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  16 in total

Review 1.  Lymphodepletional strategies in transplantation.

Authors:  Eugenia Page; Jean Kwun; Byoungchol Oh; Stuart Knechtle
Journal:  Cold Spring Harb Perspect Med       Date:  2013-07-01       Impact factor: 6.915

2.  Discrepancy in the kinetics of total and active anti-thymocyte globulin blood concentrations in recipients of allogeneic hematopoietic stem cell transplantation.

Authors:  Akiko Yamane; Takehiko Mori; Jun Kato; Yukako Ono; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2011-03-08       Impact factor: 2.490

Review 3.  Immunomodulation with rabbit anti-thymocyte globulin in solid organ transplantation.

Authors:  Giovanbattista Ippoliti; Marco Lucioni; Giuseppe Leonardi; Marco Paulli
Journal:  World J Transplant       Date:  2015-12-24

Review 4.  Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.

Authors:  Jeannine S McCune; Meagan J Bemer; Janel Long-Boyle
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

5.  Population pharmacokinetic modeling of Thymoglobulin(®) in children receiving allogeneic-hematopoietic cell transplantation: towards improved survival through individualized dosing.

Authors:  Rick Admiraal; Charlotte van Kesteren; Cornelia M Jol-van der Zijde; Maarten J D van Tol; Imke H Bartelink; Robbert G M Bredius; Jaap Jan Boelens; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2015-04       Impact factor: 6.447

6.  Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin.

Authors:  Albert C Yeh; Paul V O'Donnell; Gary Schoch; Paul J Martin; Chris McFarland; Jeannine S McCune; Jason P Cooper; Kris Doney; Mary E D Flowers; Mohamed L Sorror; Frederick R Appelbaum; Barry E Storer; Ted Gooley; H Joachim Deeg
Journal:  Bone Marrow Transplant       Date:  2021-11-05       Impact factor: 5.174

7.  Targeting of natural killer cells by rabbit antithymocyte globulin and campath-1H: similar effects independent of specificity.

Authors:  Diana Stauch; Annelie Dernier; Elizabeth Sarmiento Marchese; Kristina Kunert; Hans-Dieter Volk; Johann Pratschke; Katja Kotsch
Journal:  PLoS One       Date:  2009-03-05       Impact factor: 3.240

Review 8.  Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection.

Authors:  Emma D Deeks; Gillian M Keating
Journal:  Drugs       Date:  2009-07-30       Impact factor: 9.546

9.  Anti-thymocyte globulin for conditioning in matched unrelated donor hematopoietic cell transplantation provides comparable outcomes to matched related donor recipients.

Authors:  D A Portier; R T Sabo; C H Roberts; D S Fletcher; J Meier; W B Clark; M C Neale; M H Manjili; J M McCarty; H M Chung; A A Toor
Journal:  Bone Marrow Transplant       Date:  2012-05-14       Impact factor: 5.483

10.  Total and active rabbit antithymocyte globulin (rATG;Thymoglobulin) pharmacokinetics in pediatric patients undergoing unrelated donor bone marrow transplantation.

Authors:  Sandra K Call; Kimberly A Kasow; Raymond Barfield; Renee Madden; Wing Leung; Edwin Horwitz; Paul Woodard; John C Panetta; Sharyn Baker; Rupert Handgretinger; John Rodman; Gregory A Hale
Journal:  Biol Blood Marrow Transplant       Date:  2009-02       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.